Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 19.66 CNY, compared to the current stock price of 16.18 CNY [5]. Core Insights - The company reported a stable overall performance in H1 2025, with a slight decline in revenue but a significant increase in net profit [1]. - The company has undergone a change in control to China Resources Sanjiu, which is expected to enhance business collaboration and operational efficiency [3]. - The company is focusing on innovation and has a robust pipeline of projects, particularly in cardiovascular, neurological, and digestive fields [4][8][9]. Financial Performance - In H1 2025, the company achieved revenue of 4.288 billion CNY, a year-on-year decrease of 1.91%, while net profit reached 775 million CNY, an increase of 16.97% [1]. - The pharmaceutical industrial segment generated 3.879 billion CNY in revenue, down 0.45% year-on-year, while the pharmaceutical commercial segment saw a larger decline of 14.88% [2]. - The company expects revenue growth rates of 3.2%, 6.1%, and 6.8% for 2025, 2026, and 2027 respectively, with net profit growth rates of 23.0%, 10.2%, and 10.8% [9]. Business Segments - The cardiovascular and metabolic segment has 26 projects in the pipeline, with 10 being innovative drugs [8]. - The neurological and psychiatric segment has 16 projects, including innovative drugs targeting various conditions [8]. - The digestive segment has 13 projects, with several in advanced clinical trial stages [9]. Strategic Developments - The company has completed a "100-day integration" with China Resources Sanjiu, focusing on business stability and team cohesion [3]. - The company is advancing its "Four Reshaping" strategy to enhance management systems and achieve strategic synergies [3].

Group 1 - The core point of the news is that Green Leaf Pharmaceutical (02186.HK) has completed patient enrollment for its Phase III clinical trial of the innovative drug Ruoxinlin® (Toralacitinib) for treating Generalized Anxiety Disorder (GAD) [1] - The Phase III trial is a multi-center, randomized, double-blind, placebo-controlled study involving 555 patients, with the primary endpoint being the change in Hamilton Anxiety Scale (HAM-A) scores from baseline at week 8 [1] - The company expects to complete the clinical trial by the end of this year and submit a marketing application for this indication [1] Group 2 - Generalized Anxiety Disorder is the most common mental disorder in China, affecting approximately 53.1 million people as of 2021, with a long duration and high recurrence rate impacting patients' quality of life [1] - Ruoxinlin® is expected to be the first drug globally approved for treating GAD that acts as a triple reuptake inhibitor of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) [1] - Current first-line treatments for GAD include SSRIs and SNRIs, which have common side effects leading to low patient compliance and treatment discontinuation [2] Group 3 - Ruoxinlin® is the first domestically developed innovative drug for treating depression in China, having been approved for market since 2022, and has shown efficacy and safety in clinical settings [2] - Clinical trials have demonstrated that Ruoxinlin® significantly improves depression symptoms without causing insomnia, sedation, or affecting sexual function, weight, and lipid metabolism [2] - The drug also shows potential anxiolytic effects, improving HAM-A scores and other anxiety-related measures while providing antidepressant benefits [2]

Core Insights - The approval of the second global Phase III clinical trial for the drug Lisatoclax (brand name: Lishengtuo®) has led to a significant increase in the stock price of Ascentage Pharma-B (06855), reaching a new high of 95.35 HKD on August 18, with a year-to-date increase of 100.88% [1][2] Company Developments - Ascentage Pharma announced that the global Phase III clinical study (GLORA-4) for Lisatoclax in combination with Azacitidine (AZA) for newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) patients has received approval from the FDA and EMA [1][2] - The GLORA-4 study is a multi-center, randomized, double-blind trial aimed at evaluating the efficacy and safety of Lisatoclax combined with AZA compared to placebo plus AZA in adult HR-MDS patients [2][3] - The study has already commenced patient enrollment globally, with the first patients enrolled in China and Europe [2] Market Context - MDS is characterized by a significant age-related incidence, with a yearly incidence rate of 22 per 100,000 in individuals over 65 years old, and a median diagnosis age of 70 years [2] - The transformation rate to acute myeloid leukemia (AML) in high-risk MDS patients is alarmingly high, with a 5-year transformation rate of 40-60% [2][3] Product Efficacy - Lisatoclax is a novel oral Bcl-2 selective inhibitor that restores normal apoptosis in cancer cells, showing promising clinical benefits in previous studies [3][4] - In preliminary studies presented at major conferences, Lisatoclax combined with AZA achieved an overall response rate (ORR) of 75% in treatment-naive MDS patients, significantly higher than existing therapies [4][5] Future Prospects - The successful execution of the GLORA-4 study is expected to accelerate the clinical development and registration process for Lisatoclax in MDS indications [6] - The company aims to address unmet clinical needs globally, with hopes that Lisatoclax will become the first approved targeted therapy for first-line treatment of high-risk MDS patients [5][6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 自願性公告 若欣林®治療廣泛性焦慮障礙的 中國Ⅲ期臨床試驗完成所有患者入組 綠葉製藥集團 有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董事會（「董 事 會」）宣 佈，本 集 團 自 主 研 發 的1類創新藥若欣林® （鹽 酸 托 魯 地 文 拉 法 辛 緩 釋 片）用 於 治 療 廣 泛 性 焦 慮 障 礙 的 Ⅲ 期 臨 床 試 驗 已 完 成 所 有 患 者 入 組。 該 項 Ⅲ 期 臨 床 試 驗 為 一 項 多 中 心、隨 機、雙 盲、安 慰 劑 對 照 的 研 究，以 評 估 若 欣 林®治 療 廣 泛 性 焦 慮 障 礙 的 安 全 性 和 有 效 性。試 ...

Group 1 - The company has received a "Notice of Acceptance" from the National Medical Products Administration regarding its clinical trial application for HSK39297 tablets, which are intended for the treatment of age-related macular degeneration (AMD) and generalized myasthenia gravis (gMG) [1][2] - AMD is a degenerative disease affecting the macula, with a global prevalence of approximately 8.7%, and it is estimated that nearly 300 million people will be affected by 2040 [2] - HSK39297 is a novel small molecule drug with independent intellectual property rights, showing clear targets, confirmed efficacy, and good safety, indicating a high benefit/risk ratio for clinical application [3] Group 2 - The drug has previously submitted IND applications for complement-mediated primary or secondary glomerular diseases and complement-mediated hemolytic diseases, with ongoing clinical studies for IgA nephropathy and paroxysmal nocturnal hemoglobinuria [3] - The current acceptance pertains specifically to clinical trials for AMD and gMG, addressing the clinical drug shortage faced by patients [3][4]

Core Viewpoint - The surge of pharmaceutical companies listing on the Hong Kong Stock Exchange (HKEX) reflects a growing interest in the biotech sector, driven by innovative drug development and supportive regulatory frameworks [1][2][3]. Group 1: Market Activity - In 2023, 14 biopharmaceutical and medical device companies have listed on HKEX, raising a total of 182.25 billion HKD, with 36 more companies in the pipeline [2]. - The rapid development of innovative drugs is closely linked to the increase in listings, with 43 innovative drugs approved in the first half of the year, a 59% year-on-year increase [2]. - The Hang Seng Biotechnology Index has doubled in value this year, indicating strong market performance in the biotech sector [2]. Group 2: Regulatory and Capital Support - The introduction of the "Science and Technology Enterprises Special Line" and the 18A listing rule has facilitated early and customized listing guidance for innovative drug companies [3]. - Since the implementation of the 18A rule, 77 biotech companies have gone public, demonstrating the positive impact of regulatory reforms on the industry [3]. - Increased liquidity and capital inflow, particularly from foreign investments, have significantly improved the valuation and liquidity of the biotech sector [3]. Group 3: Company Performance and Evaluation Criteria - Companies with strong clinical data and rapid pipeline advancement, particularly in oncology, autoimmune diseases, and metabolic disorders, are attracting high valuations [6]. - The focus of investors is shifting from the quantity of drug pipelines to the quality and clinical value of the research outcomes [5][6]. - Successful recent listings, such as Zhonghui Biotech-B and Weilizhibo-B, highlight the market's preference for companies with innovative therapies and strong clinical trial results [6].

Investment Rating - The report maintains a "Buy" rating for the company, with expected earnings per share (EPS) of 1.80, 2.05, and 2.31 RMB for the years 2025 to 2027, respectively [4]. Core Insights - The company's revenue for the first half of 2025 reached 14.81 billion RMB, a year-on-year increase of 5%, while the net profit attributable to shareholders decreased by 24% to 1.82 billion RMB [2]. - The CHC (Consumer Health Care) business faced short-term pressure, with a revenue decline of 18.4% to approximately 6.08 billion RMB, attributed to lower incidence rates of respiratory diseases and adjustments in retail channels [2]. - The prescription drug business continued to grow, achieving a revenue increase of 15.2% to approximately 2.78 billion RMB, with market share steadily improving due to opportunities from national procurement [2][3]. Summary by Sections Performance Review - In 1H25, the company reported a revenue of 14.81 billion RMB, up 5% year-on-year, but a net profit of 1.82 billion RMB, down 24% year-on-year [2]. - For Q2 2025, revenue was 7.96 billion RMB, a 17% increase year-on-year, while net profit fell 47% to 0.55 billion RMB [2]. Business Analysis - The CHC business is under short-term pressure, with a revenue drop of 18.4% to about 6.08 billion RMB, influenced by lower respiratory disease rates and retail channel adjustments [2]. - The prescription drug segment saw a revenue increase of 15.2% to approximately 2.78 billion RMB, benefiting from national procurement opportunities [2]. Innovation and Development - The company is expanding its product pipeline through commercial partnerships and product introductions, including a joint development agreement for a weight loss and diabetes treatment drug [3]. - The company is also conducting Phase I clinical trials for a brain tumor treatment drug, which has received accelerated approval from the FDA [3]. Profit Forecast and Valuation - The profit forecasts for 2025 to 2027 have been adjusted to 3.01 billion, 3.42 billion, and 3.85 billion RMB, reflecting a year-on-year change of -10.62%, +13%, and +12.83%, respectively [4]. - The current price corresponds to a price-to-earnings (P/E) ratio of 17, 15, and 14 for the years 2025 to 2027 [4].

Core Viewpoint - The company, Haisco (002653.SZ), has received a "Notice of Acceptance" from the National Medical Products Administration for its drug HSK39297 tablets, targeting age-related macular degeneration (AMD) and generalized myasthenia gravis (gMG) [1] Group 1: Drug Development Potential - HSK39297 is identified as a small molecule drug with clear targets, confirmed efficacy, and good safety profile, indicating significant development potential [1] - The drug is expected to have a high benefit/risk ratio in clinical applications, suggesting a promising future in the market [1] Group 2: Clinical Application Prospects - The drug addresses the current shortage of effective treatments for AMD and gMG, highlighting its potential to fill a critical gap in clinical medication [1] - The broad clinical application prospects of HSK39297 position it as a potentially effective treatment option for these conditions [1]

Company Updates - The company announced on August 13 that its self-developed innovative drug, Taitasip, a global first BLyS/APRIL dual-target fusion protein, has achieved the primary endpoint in the Phase III clinical trial for treating primary Sjögren's syndrome (pSS) and will soon submit a marketing application to the National Medical Products Administration (NMPA) [1] - Taitasip has shown significant clinical efficacy, with Phase II clinical data indicating a reduction of 4.3 points in the ESSDAI score after 24 weeks of treatment with 160mg, outperforming the placebo [1] - The drug has received multiple authoritative guideline recommendations in China and has been granted Fast Track designation by the FDA for its pSS indication, allowing for a global multi-center Phase III clinical trial [1] Product Development - The company’s novel bispecific antibody, RC148, has received FDA approval for clinical trials in the U.S. for various advanced malignant solid tumors, marking its entry into global clinical development [2] - RC148 is expected to enhance tumor-killing responses through immune checkpoint blockade and tumor angiogenesis inhibition, indicating its international clinical value and potential for global expansion [2] - In China, RC148 is progressing smoothly in clinical research for single-agent and combination therapies for advanced solid tumors, with promising efficacy and safety observed in early trials [2] Financial Forecast and Valuation - The company maintains its net profit loss forecast for 2025 and 2026 at 915 million yuan and 333 million yuan, respectively [2] - Positive Phase III clinical results for Taitasip are expected to enhance its future value, while the FDA approval for RC148's Phase II trial is anticipated to boost its global value [2] - Based on a DCF model, the company has raised its target price by 24.8% to HKD 95.34, indicating a potential upside of 23.1% from the current stock price [2]

Core Insights - China's innovative drug development is transitioning from imitation to independent innovation, with significant achievements in international markets [1][5][7] - The number of new drugs under research in China is projected to rank second globally by 2024, indicating a growing industry scale [3][6] - The domestic innovative drug market has seen over 110 new drugs approved since the 14th Five-Year Plan, with a market size reaching 100 billion yuan [6][12] R&D Advancements - Domestic innovative drugs now account for over half of the clinical trials at Beijing University Cancer Hospital, showcasing rapid development in this sector [1][3] - Multiple innovative drugs have been approved in the first half of this year, including treatments for rare diseases and other conditions, marking breakthroughs in previously unmet clinical needs [5][6] International Expansion - Chinese pharmaceutical companies are increasingly engaging in overseas licensing agreements, with over 90 transactions completed in 2024, totaling more than 50 billion USD [7][9] - Notable licensing deals include a 60 billion USD agreement between 3SBio and Pfizer, and a 125 billion USD deal between Hengrui Medicine and GlaxoSmithKline [9][10] Policy Support - The Chinese government is implementing policies to support the entire lifecycle of innovative drugs, including expedited approval processes and financial investments [11][14] - Recent measures include a 30-day approval timeline for innovative drugs and the establishment of funds to support research and development in the pharmaceutical sector [12][15] Market Dynamics - The innovative drug market is experiencing a surge in both quantity and quality, with a notable increase in the approval of new drugs that cater to both domestic and international patients [7][8] - The market is evolving to include a diverse range of biopharmaceuticals, including monoclonal antibodies and CAR-T cell therapies, reflecting a shift towards cutting-edge technologies [10][11]